Alaya.bio

Alaya.bio is a pioneering biotechnology company dedicated to advancing in vivo gene delivery platforms, particularly in the field of CAR T-cell immunotherapy. This proprietary technology relies on targeted polymeric nanoparticles, consisting of a lentiviral vector encapsulated by a biodegradable polymer, capable of targeting and transducing T cells. The platform technology aims to enhance the transduction efficiency of resting cells (including T cells, NK cells, and stem cells). It can be used in vitro (as part of a rapid manufacturing process) or in vivo (for in situ transduction within patients after systemic administration).